VERAXA Biotech AG (NASDAQ: VRXA) has begun trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ as of June 11, 2026, following the successful conclusion of a business combination with Voyager Acquisition Corp. (NASDAQ: VACH). The company is now positioned as ‘One to Watch’ in the biotechnology sector, with a diversified oncology pipeline spanning multiple therapeutic modalities and indications.
VERAXA is advancing a pipeline that includes monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and its proprietary BiTAC-based therapeutic formats. The BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. This approach addresses a key challenge in oncology: delivering potent therapies to cancer cells while sparing healthy tissue.
The company’s focus on ADCs and T-cell engagers (TCEs) places it within two rapidly growing segments of the global oncology therapeutics market. ADCs, which combine the targeting ability of antibodies with the cell-killing power of cytotoxic drugs, have seen significant investment and clinical success in recent years. TCEs, which redirect immune cells to attack tumors, represent another promising area. By advancing assets in both categories, VERAXA aims to capture opportunities across multiple mechanisms of action.
In addition to its internal pipeline, VERAXA is pursuing selected partnerships to contribute value to developments in complementary therapeutic sectors, such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs). These collaborations could expand the company’s reach beyond its core platforms and into emerging fields that combine antibodies with radiation or genetic therapies.
The company’s vision is to deliver the next wave of smart cancer therapies with curative potential. Its proprietary BiTAC platform is central to this mission, offering a differentiated approach to conditional activation. For investors, the listing on NASDAQ provides a liquid market for shares and increased visibility. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Industry observers will be watching VERAXA’s progress as it seeks to advance its pipeline through clinical development. The success of its BiTAC platform and ADC/TCE programs could have significant implications for patients with solid tumors, where treatment options remain limited. The company’s ability to form strategic partnerships may also enhance its chances of bringing new therapies to market.
